Anti-TNF-α biosimilars showed a 91% drug survival rate at 12 months, with no significant differences between infliximab, etanercept, and adalimumab. Long-term effectiveness and safety of anti-TNF-α ...
Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Efficacy is just one of many factors that should be considered when choosing therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback